Research Reports

Summary

OrthoPediatrics Corp. filed an 8-K to furnish its April 2026 Investor Presentation (Exhibit 99.1), which outlines forward-looking strategic priorities, market sizing, product portfolio expansion, R&D and M&A initiatives, and non-GAAP financial measures—but discloses no new earnings results, acquisitions, executive changes, or material agreements.

Key takeaways

Exhibit 99.1 is an investor presentation dated April 2026, furnished under Item 7.01—not filed—and contains no new financial results for any reporting period.

The presentation estimates the global pediatric orthopedic addressable market at $6.2B, with U.S. target market of $1.6B and specialty bracing segment of $0.5B as of January 2025.

OrthoPediatrics reports consistent YoY revenue growth since inception, citing $236.3M total revenue in 2025 and a 2016–2025 CAGR; no 2026 revenue figure or guidance is provided.

The company acquired Boston Orthotics & Prosthetics in January 2024 for $22M cash, establishing its Specialty Bracing division and adding 26 pediatric O&P clinics in 10 states.

Non-GAAP metrics—including Adjusted EBITDA, adjusted diluted (loss) EPS, and free cash flow—are defined and reconciled in the presentation but no actual values are disclosed.

Full analysis

This 8-K serves solely to furnish OrthoPediatrics’ April 2026 Investor Presentation under Item 7.01, which is expressly stated as non-filed and not subject to liability under Section 18 of the Exchange Act. The presentation provides strategic context—including market sizing ($6.2B global TAM), historical revenue progression ($236.3M in 2025), and operational pillars—but contains no newly reported financial results, updated guidance, or disclosures triggering Tier 1 events like earnings (Item 2.02), financing (Item 2.03), or executive changes (Item 5.02). The only concrete transactional fact is the January 5, 2024 acquisition of Boston Orthotics & Prosthetics for $22M cash, which expanded OrthoPediatrics’ presence in specialty bracing and added clinical infrastructure. While the presentation defines non-GAAP metrics and references reconciliations, it does not disclose actual values for revenue, net income, EPS, or cash flow for any period—rendering it informational rather than operational. Investors should treat this filing as supplementary background, not a source of current financial performance or forward-looking commitments beyond the generic forward-looking statements disclaimer included in Exhibit 99.1.